Markets

Ocera Therapeutics (OCRX) Soars: Stock Adds 11.8% in Session - Tale of the Tape

Ocera Therapeutics, Inc. ( OCRX ) was a big mover last session, as its shares rose nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the trend for the company since May 19, as the stock is now trading above the volatile price range of $6.80 to $7.35.

In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Ocera Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Other stocks worth considering in the Med-Biomed industry include ANI Pharmaceuticals, Inc. ( ANIP ), Illumina Inc. ( ILMN ) and Gilead Sciences Inc. ( GILD ). All these stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OCERA THERAPEUT (OCRX): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD ANIP ILMN

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More